IP Library Granted Patent US 8,216,794
Granted Patent B2
US 8,216,794 · App. 12/802,335 · Granted Jul 10, 2012

Extracellular serine protease

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,216,794
App. No.
12/802,335
Granted
Jul 10, 2012
Kind
B2
Abstract

The present invention provides a DNA encoding a novel extracellular serine protease termed Tumor Antigen Derived Gene-14 (TADG-14) which is overexpressed in ovarian, breast and colon carcinoma samples. Also provided are vector and host cells capable of expressing the DNA of the present invention, as well as the uses of the DNA and protein of the present invention. Also provided is a TADG-14 protein variant that has a potential role for detecting and targeting of ovarian carcinomas.

Claims (12)

1. A method of diagnosing ovarian cancer in an individual, comprising the steps of:

obtaining a biological sample from an individual;

contacting said sample with an antibody that binds to SEQ ID NO: 75; thereby detecting in the sample a TADG-14 protein variant comprising the amino acid sequence of SEQ ID NO: 75, wherein the presence of TADG-14 variant in the sample is indicative of the presence of ovarian cancer in the individual.

2. The method of claim 1 , wherein the biological sample is blood, interstitial fluid, ascites fluid, tumor tissue biopsy, or circulating tumor cells.

3. The method of claim 1 , wherein detection of the TADG-14 protein variant comprises a Western blot, an ELISA sandwich assay, a radioimmunoassay, or flow cytometry.

4. A method of diagnosing ovarian cancer in an individual, comprising the steps of:

obtaining a biological sample from an individual;

extracting mRNA from said sample;

deriving cDNA from said mRNA;

reacting said cDNA with primers consisting of SEQ ID NO: 73 and SEQ ID NO: 74; and

measuring the presence of a transcript for TADG-14 gene variant encoding the TADG-14 protein variant comprising the sequence of SEQ ID NO: 75 wherein the presence of transcript for TADG-14 gene variant encoding the TADG-14 protein variant comprising the sequence of SEQ ID NO: 75 in the sample indicates that the individual has ovarian cancer.

5. The method of claim 4 , wherein the biological sample is blood, interstitial fluid, ascites fluid, tumor tissue biopsy, or circulating tumor cells.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2017
From: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
To: BIOVENTURES, LLC
Reel/Frame 044037/0496 →